World Pharma News Digest - 13.10.2014
50 views
Skip to first unread message
Ruslan David
Oct 13, 2014, 8:52:13 AM10/13/14
to worldph...@googlegroups.com
Bayer supports World Thrombosis Day as founding global partner
As founding global partner, Bayer HealthCare joins the International Society on Thrombosis and Haemostasis (ISTH) today to launch the annual World Thrombosis Day. Held for the first time, World Thrombosis Day is dedicated to focusing attention on the underlying condition responsible for the three leading causes of cardiovascular death - heart attack, stroke and venous thromboembolism (VTE, or venous blood clots).
Read more...
http://www.worldpharmanews.com/bayer/2915-bayer-supports-world-thrombosis-day-as-founding-global-partner
Mechanism that repairs brain after stroke discovered
A previously unknown mechanism through which the brain produces new nerve cells after a stroke has been discovered at Lund University and Karolinska Institute in Sweden. The findings have been published in the journal Science. A stroke is caused by a blood clot blocking a blood vessel in the brain, which leads to an interruption of blood flow and therefore a shortage of oxygen.
Read more...
http://www.worldpharmanews.com/research/2914-mechanism-that-repairs-brain-after-stroke-discovered
Positive results from Phase IIb benralizumab study in severe asthma
AstraZeneca has announced that The Lancet Respiratory Medicine has published positive safety and efficacy data from a Phase IIb study evaluating benralizumab, a novel investigational monoclonal antibody, in patients with severe, uncontrolled asthma and elevated levels of eosinophils, a type of inflammatory white blood cell.
Read more...
http://www.worldpharmanews.com/astrazeneca/2913-positive-results-from-phase-iib-benralizumab-study-in-severe-asthma
New data on the global economic impact and burden of preventable blindness and vision impairment
To highlight the critical need for access to eye care and regular eye examinations, Novartis and its eye care division, Alcon, are introducing new data on World Sight Day, highlighting the economic impact and burden that blindness and vision impairment can have on societies and individuals across the globe.
Read more...
http://www.worldpharmanews.com/novartis/2912-new-data-on-the-global-economic-impact-and-burden-of-preventable-blindness-and-vision-impairment
Probiotic yogurt could help protect against heavy metal poisoning
New research shows probiotic yogurt can reduce the uptake of certain heavy metals and environmental toxins by up to 78% in pregnant women. Led by Scientists at Lawson Health Research Institute's Canadian Centre for Human Microbiome and Probiotic Research, this study provides the first clinical evidence that a probiotic yogurt can be used to reduce the deadly health risks associated with mercury and arsenic.
Read more...
http://www.worldpharmanews.com/research/2911-probiotic-yogurt-could-help-protect-against-heavy-metal-poisoning
A universal Ebola drug target
University of Utah biochemists have reported a new drug discovery tool against the Ebola virus. According to a study published in this week's online edition of Protein Science, they have produced a molecule, known as a peptide mimic, that displays a functionally critical region of the virus that is universally conserved in all known species of Ebola.
Read more...
http://www.worldpharmanews.com/research/2910-a-universal-ebola-drug-target
GSK commits further funding to advance bioelectronics research with creation of $5 million Innovation Challenge Fund
GSK has announced a $5 million Innovation Challenge Fund (ICF) to further encourage and advance collaborative research as part of its effort to develop bioelectronic medicines. The fund will support academic groups and small companies who want to develop solutions for GSK's Bioelectronics Innovation Challenge, which was developed by a group of leading scientists from around the world.
Read more...
http://www.worldpharmanews.com/gsk/2909-gsk-commits-further-funding-to-advance-bioelectronics-research-with-creation-of-5-million-innovation-challenge-fund
Attacking type 2 diabetes from a new direction with encouraging results
Type 2 diabetes affects an estimated 28 million Americans according to the American Diabetes Association, but medications now available only treat symptoms, not the root cause of the disease. New research from Rutgers shows promising evidence that a modified form of a different drug, niclosamide - now used to eliminate intestinal parasites - may hold the key to battling the disease at its source.
Read more...
http://www.worldpharmanews.com/research/2908-attacking-type-2-diabetes-from-a-new-direction-with-encouraging-results
The 2014 Nobel Prize in Physiology or Medicine
The Nobel Assembly at Karolinska Institutet has today decided to award The 2014 Nobel Prize in Physiology or Medicine with one half to John O'Keefe and the other half jointly to May-Britt Moser and Edvard I. Moser for their discoveries of cells that constitute a positioning system in the brain.
Read more...
http://www.worldpharmanews.com/research/2907-the-2014-nobel-prize-in-physiology-or-medicine
Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb's novel immunotherapy in combination treatments for NSCLC
Novartis announced today that it has entered into a clinical collaboration with Bristol-Myers Squibb Company (NYSE: BMY) to evaluate the safety, tolerability and preliminary efficacy of three molecularly targeted compounds in combination with Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab), in Phase I/II trials of patients with non-small cell lung cancer (NSCLC).
Read more...
http://www.worldpharmanews.com/novartis/2906-novartis-announces-clinical-collaboration-to-evaluate-bristol-myers-squibbs-novel-immunotherapy-in-combination-treatments-for-nsclc
Common painkillers combined with other drugs may cause high risk of GI bleeding
Nonsteroidal anti-inflammatory drugs (NSAIDs) - such as ibuprofen and aspirin - increase one's risk of upper gastrointestinal bleeding. When taken in combination with other drugs, this risk is significantly higher, according to new research appearing in the October issue of Gastroenterology, the official journal of the American Gastroenterological Association.
Read more...
http://www.worldpharmanews.com/research/2905-common-painkillers-combined-with-other-drugs-may-cause-high-risk-of-gi-bleeding
New drug-delivery capsule may replace injections
Given a choice, most patients would prefer to take a drug orally instead of getting an injection. Unfortunately, many drugs, especially those made from large proteins, cannot be given as a pill because they get broken down in the stomach before they can be absorbed. To help overcome that obstacle, researchers at MIT and Massachusetts General Hospital (MGH) have devised a novel drug capsule coated with tiny needles that can inject drugs directly into the lining of the stomach after the capsule is swallowed.
Read more...
http://www.worldpharmanews.com/research/2904-new-drug-delivery-capsule-may-replace-injections
Bayer closes acquisition of consumer care business of Merck & Co., Inc., United States, for USD 14.2 billion
Bayer has completed the acquisition of the consumer care business of the U.S. pharmaceuticals group Merck & Co., Inc., Whitehouse Station, New Jersey. The transaction closed on October 1, 2014, following receipt of required antitrust approvals.
Read more...
http://www.worldpharmanews.com/bayer/2903-bayer-closes-acquisition-of-consumer-care-business-of-merck-a-co-inc-united-states-for-usd-142-billion
Pfizer and Kyowa Hakko Kirin to collaborate on immuno-oncology combination study
Pfizer Inc. (NYSE:PFE) and Kyowa Hakko Kirin (Tokyo:4151), have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's PF-05082566, an investigational, fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137), a protein involved in regulation of immune cell activation, proliferation and survival, with Kyowa Hakko Kirin's anti-CCR4 antibody mogamulizumab,
Read more...
http://www.worldpharmanews.com/pfizer/2902-pfizer-and-kyowa-hakko-kirin-to-collaborate-on-immuno-oncology-combination-study
Transplant drug could boost the power of brain tumor treatments
Every day, organ transplant patients around the world take a drug called rapamycin to keep their immune systems from rejecting their new kidneys and hearts. New research suggests that the same drug could help brain tumor patients by boosting the effect of new immune-based therapies.
Read more...
http://www.worldpharmanews.com/research/2901-transplant-drug-could-boost-the-power-of-brain-tumor-treatments
New research outlines promising therapies for small cell lung cancer
Two recently published studies by a research team at University Hospitals (UH) Case Medical Center Seidman Cancer Center have the potential to advance treatments for small cell lung cell cancer (SCLC). This aggressive form of lung cancer has seen no treatment advances in 30 years and "is a disease in urgent need of new drug therapies," write the study's authors.
Read more...
http://www.worldpharmanews.com/research/2900-new-research-outlines-promising-therapies-for-small-cell-lung-cancer
Novo Nordisk establishes new obesity research unit in Seattle
Novo Nordisk has announced that the company will establish a new obesity research unit in Seattle, Washington, in the US. The new unit is a result of Novo Nordisk's increasing focus on treatment of obesity. Its main task will be to identify novel approaches and targets for obesity treatments while increasing the scientific understanding of existing obesity targets.
Read more...
http://www.worldpharmanews.com/novonordisk/2899-novo-nordisk-establishes-new-obesity-research-unit-in-seattle
Discrepancies in access to new cancer drugs revealed
Access to potentially life-extending cancer drugs varies significantly in different regions of the world, two new studies show at the ESMO 2014 Congress in Madrid, Spain. Researchers say the results demonstrate the need for better collaboration between doctors and health authorities on an international scale, to ensure patients have access to the best treatments.
Read more...
http://www.worldpharmanews.com/research/2898-discrepancies-in-access-to-new-cancer-drugs-revealed
MedImmune and Cancer Research UK establish joint CRUK-MEDI Alliance Laboratory
AstraZeneca today announced that MedImmune, its global biologics research and development arm, and Cancer Research UK, with its commercial arm, Cancer Research Technology (CRT), have entered into an innovative collaboration to establish a joint laboratory in Cambridge, UK.
Read more...
http://www.worldpharmanews.com/astrazeneca/2897-medimmune-and-cancer-research-uk-establish-joint-cruk-medi-alliance-laboratory
Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy
Boehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleic acid)-based drug development, have announced an exclusive global license and development collaboration. The new collaboration focuses on CureVac's CV9202, a novel investigational therapeutic mRNA vaccine, in early clinical development for the treatment of lung cancer.
Read more...
http://www.worldpharmanews.com/boehringer-ingelheim/2896-boehringer-ingelheim-and-curevac-announce-collaboration-to-develop-next-generation-lung-cancer-immunotherapy
PharmaNews.eu / Latest News
Nanoparticle research could enhance drug delivery through skin
http://www.pharmanews.eu/research-and-development/1479-nanoparticle-research-could-enhance-drug-delivery-through-skin
Discovery helps to spot what makes a good drug
http://www.pharmanews.eu/research-and-development/1478-discovery-helps-to-spot-what-makes-a-good-drug
Novartis presents oncology research advances with new data on Zykadia(TM), Afinitor® and key pipeline compounds at ESMO 2014
http://www.pharmanews.eu/novartis/1477-novartis-presents-oncology-research-advances-with-new-data-on-zykadiatm-afinitorr-and-key-pipeline-compounds-at-esmo-2014
Small molecule antibodies for cancer immunotherapy: ImmuSmol raises 500 000 euros for in vivo proof-of concept
http://www.pharmanews.eu/research-and-development/1476-small-molecule-antibodies-for-cancer-immunotherapy-immusmol-raises-500-000-euros-for-in-vivo-proof-of-concept
mHealth Summit Europe 2015 and eHealth Week join forces
http://www.pharmanews.eu/conferences-and-events/1475-mhealth-summit-europe-2015-and-ehealth-week-join-forces
Eating is addictive but sugar and fat are not like drugs, study says
http://www.pharmanews.eu/research-and-development/1474-eating-is-addictive-but-sugar-and-fat-are-not-like-drugs-study-says
Scientists discover how to 'switch off' autoimmune diseases
http://www.pharmanews.eu/research-and-development/1473-scientists-discover-how-to-switch-off-autoimmune-diseases
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
With best regards,
As founding global partner, Bayer HealthCare joins the International Society on Thrombosis and Haemostasis (ISTH) today to launch the annual World Thrombosis Day. Held for the first time, World Thrombosis Day is dedicated to focusing attention on the underlying condition responsible for the three leading causes of cardiovascular death - heart attack, stroke and venous thromboembolism (VTE, or venous blood clots).
Read more...
http://www.worldpharmanews.com/bayer/2915-bayer-supports-world-thrombosis-day-as-founding-global-partner
Mechanism that repairs brain after stroke discovered
A previously unknown mechanism through which the brain produces new nerve cells after a stroke has been discovered at Lund University and Karolinska Institute in Sweden. The findings have been published in the journal Science. A stroke is caused by a blood clot blocking a blood vessel in the brain, which leads to an interruption of blood flow and therefore a shortage of oxygen.
Read more...
http://www.worldpharmanews.com/research/2914-mechanism-that-repairs-brain-after-stroke-discovered
Positive results from Phase IIb benralizumab study in severe asthma
AstraZeneca has announced that The Lancet Respiratory Medicine has published positive safety and efficacy data from a Phase IIb study evaluating benralizumab, a novel investigational monoclonal antibody, in patients with severe, uncontrolled asthma and elevated levels of eosinophils, a type of inflammatory white blood cell.
Read more...
http://www.worldpharmanews.com/astrazeneca/2913-positive-results-from-phase-iib-benralizumab-study-in-severe-asthma
New data on the global economic impact and burden of preventable blindness and vision impairment
To highlight the critical need for access to eye care and regular eye examinations, Novartis and its eye care division, Alcon, are introducing new data on World Sight Day, highlighting the economic impact and burden that blindness and vision impairment can have on societies and individuals across the globe.
Read more...
http://www.worldpharmanews.com/novartis/2912-new-data-on-the-global-economic-impact-and-burden-of-preventable-blindness-and-vision-impairment
Probiotic yogurt could help protect against heavy metal poisoning
New research shows probiotic yogurt can reduce the uptake of certain heavy metals and environmental toxins by up to 78% in pregnant women. Led by Scientists at Lawson Health Research Institute's Canadian Centre for Human Microbiome and Probiotic Research, this study provides the first clinical evidence that a probiotic yogurt can be used to reduce the deadly health risks associated with mercury and arsenic.
Read more...
http://www.worldpharmanews.com/research/2911-probiotic-yogurt-could-help-protect-against-heavy-metal-poisoning
A universal Ebola drug target
University of Utah biochemists have reported a new drug discovery tool against the Ebola virus. According to a study published in this week's online edition of Protein Science, they have produced a molecule, known as a peptide mimic, that displays a functionally critical region of the virus that is universally conserved in all known species of Ebola.
Read more...
http://www.worldpharmanews.com/research/2910-a-universal-ebola-drug-target
GSK commits further funding to advance bioelectronics research with creation of $5 million Innovation Challenge Fund
GSK has announced a $5 million Innovation Challenge Fund (ICF) to further encourage and advance collaborative research as part of its effort to develop bioelectronic medicines. The fund will support academic groups and small companies who want to develop solutions for GSK's Bioelectronics Innovation Challenge, which was developed by a group of leading scientists from around the world.
Read more...
http://www.worldpharmanews.com/gsk/2909-gsk-commits-further-funding-to-advance-bioelectronics-research-with-creation-of-5-million-innovation-challenge-fund
Attacking type 2 diabetes from a new direction with encouraging results
Type 2 diabetes affects an estimated 28 million Americans according to the American Diabetes Association, but medications now available only treat symptoms, not the root cause of the disease. New research from Rutgers shows promising evidence that a modified form of a different drug, niclosamide - now used to eliminate intestinal parasites - may hold the key to battling the disease at its source.
Read more...
http://www.worldpharmanews.com/research/2908-attacking-type-2-diabetes-from-a-new-direction-with-encouraging-results
The 2014 Nobel Prize in Physiology or Medicine
The Nobel Assembly at Karolinska Institutet has today decided to award The 2014 Nobel Prize in Physiology or Medicine with one half to John O'Keefe and the other half jointly to May-Britt Moser and Edvard I. Moser for their discoveries of cells that constitute a positioning system in the brain.
Read more...
http://www.worldpharmanews.com/research/2907-the-2014-nobel-prize-in-physiology-or-medicine
Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb's novel immunotherapy in combination treatments for NSCLC
Novartis announced today that it has entered into a clinical collaboration with Bristol-Myers Squibb Company (NYSE: BMY) to evaluate the safety, tolerability and preliminary efficacy of three molecularly targeted compounds in combination with Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab), in Phase I/II trials of patients with non-small cell lung cancer (NSCLC).
Read more...
http://www.worldpharmanews.com/novartis/2906-novartis-announces-clinical-collaboration-to-evaluate-bristol-myers-squibbs-novel-immunotherapy-in-combination-treatments-for-nsclc
Common painkillers combined with other drugs may cause high risk of GI bleeding
Nonsteroidal anti-inflammatory drugs (NSAIDs) - such as ibuprofen and aspirin - increase one's risk of upper gastrointestinal bleeding. When taken in combination with other drugs, this risk is significantly higher, according to new research appearing in the October issue of Gastroenterology, the official journal of the American Gastroenterological Association.
Read more...
http://www.worldpharmanews.com/research/2905-common-painkillers-combined-with-other-drugs-may-cause-high-risk-of-gi-bleeding
New drug-delivery capsule may replace injections
Given a choice, most patients would prefer to take a drug orally instead of getting an injection. Unfortunately, many drugs, especially those made from large proteins, cannot be given as a pill because they get broken down in the stomach before they can be absorbed. To help overcome that obstacle, researchers at MIT and Massachusetts General Hospital (MGH) have devised a novel drug capsule coated with tiny needles that can inject drugs directly into the lining of the stomach after the capsule is swallowed.
Read more...
http://www.worldpharmanews.com/research/2904-new-drug-delivery-capsule-may-replace-injections
Bayer closes acquisition of consumer care business of Merck & Co., Inc., United States, for USD 14.2 billion
Bayer has completed the acquisition of the consumer care business of the U.S. pharmaceuticals group Merck & Co., Inc., Whitehouse Station, New Jersey. The transaction closed on October 1, 2014, following receipt of required antitrust approvals.
Read more...
http://www.worldpharmanews.com/bayer/2903-bayer-closes-acquisition-of-consumer-care-business-of-merck-a-co-inc-united-states-for-usd-142-billion
Pfizer and Kyowa Hakko Kirin to collaborate on immuno-oncology combination study
Pfizer Inc. (NYSE:PFE) and Kyowa Hakko Kirin (Tokyo:4151), have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's PF-05082566, an investigational, fully humanized monoclonal antibody (mAb) that stimulates signaling through 4-1BB (CD-137), a protein involved in regulation of immune cell activation, proliferation and survival, with Kyowa Hakko Kirin's anti-CCR4 antibody mogamulizumab,
Read more...
http://www.worldpharmanews.com/pfizer/2902-pfizer-and-kyowa-hakko-kirin-to-collaborate-on-immuno-oncology-combination-study
Transplant drug could boost the power of brain tumor treatments
Every day, organ transplant patients around the world take a drug called rapamycin to keep their immune systems from rejecting their new kidneys and hearts. New research suggests that the same drug could help brain tumor patients by boosting the effect of new immune-based therapies.
Read more...
http://www.worldpharmanews.com/research/2901-transplant-drug-could-boost-the-power-of-brain-tumor-treatments
New research outlines promising therapies for small cell lung cancer
Two recently published studies by a research team at University Hospitals (UH) Case Medical Center Seidman Cancer Center have the potential to advance treatments for small cell lung cell cancer (SCLC). This aggressive form of lung cancer has seen no treatment advances in 30 years and "is a disease in urgent need of new drug therapies," write the study's authors.
Read more...
http://www.worldpharmanews.com/research/2900-new-research-outlines-promising-therapies-for-small-cell-lung-cancer
Novo Nordisk establishes new obesity research unit in Seattle
Novo Nordisk has announced that the company will establish a new obesity research unit in Seattle, Washington, in the US. The new unit is a result of Novo Nordisk's increasing focus on treatment of obesity. Its main task will be to identify novel approaches and targets for obesity treatments while increasing the scientific understanding of existing obesity targets.
Read more...
http://www.worldpharmanews.com/novonordisk/2899-novo-nordisk-establishes-new-obesity-research-unit-in-seattle
Discrepancies in access to new cancer drugs revealed
Access to potentially life-extending cancer drugs varies significantly in different regions of the world, two new studies show at the ESMO 2014 Congress in Madrid, Spain. Researchers say the results demonstrate the need for better collaboration between doctors and health authorities on an international scale, to ensure patients have access to the best treatments.
Read more...
http://www.worldpharmanews.com/research/2898-discrepancies-in-access-to-new-cancer-drugs-revealed
MedImmune and Cancer Research UK establish joint CRUK-MEDI Alliance Laboratory
AstraZeneca today announced that MedImmune, its global biologics research and development arm, and Cancer Research UK, with its commercial arm, Cancer Research Technology (CRT), have entered into an innovative collaboration to establish a joint laboratory in Cambridge, UK.
Read more...
http://www.worldpharmanews.com/astrazeneca/2897-medimmune-and-cancer-research-uk-establish-joint-cruk-medi-alliance-laboratory
Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy
Boehringer Ingelheim and CureVac, leader in mRNA (messenger ribonucleic acid)-based drug development, have announced an exclusive global license and development collaboration. The new collaboration focuses on CureVac's CV9202, a novel investigational therapeutic mRNA vaccine, in early clinical development for the treatment of lung cancer.
Read more...
http://www.worldpharmanews.com/boehringer-ingelheim/2896-boehringer-ingelheim-and-curevac-announce-collaboration-to-develop-next-generation-lung-cancer-immunotherapy
PharmaNews.eu / Latest News
Nanoparticle research could enhance drug delivery through skin
http://www.pharmanews.eu/research-and-development/1479-nanoparticle-research-could-enhance-drug-delivery-through-skin
Discovery helps to spot what makes a good drug
http://www.pharmanews.eu/research-and-development/1478-discovery-helps-to-spot-what-makes-a-good-drug
Novartis presents oncology research advances with new data on Zykadia(TM), Afinitor® and key pipeline compounds at ESMO 2014
http://www.pharmanews.eu/novartis/1477-novartis-presents-oncology-research-advances-with-new-data-on-zykadiatm-afinitorr-and-key-pipeline-compounds-at-esmo-2014
Small molecule antibodies for cancer immunotherapy: ImmuSmol raises 500 000 euros for in vivo proof-of concept
http://www.pharmanews.eu/research-and-development/1476-small-molecule-antibodies-for-cancer-immunotherapy-immusmol-raises-500-000-euros-for-in-vivo-proof-of-concept
mHealth Summit Europe 2015 and eHealth Week join forces
http://www.pharmanews.eu/conferences-and-events/1475-mhealth-summit-europe-2015-and-ehealth-week-join-forces
Eating is addictive but sugar and fat are not like drugs, study says
http://www.pharmanews.eu/research-and-development/1474-eating-is-addictive-but-sugar-and-fat-are-not-like-drugs-study-says
Scientists discover how to 'switch off' autoimmune diseases
http://www.pharmanews.eu/research-and-development/1473-scientists-discover-how-to-switch-off-autoimmune-diseases
PS: Be on top of World Pharma News. Advertise with us!
World Pharma News is the leader in coverage and distribution of the top pharma industry, research and conference news. World Pharma News is one of the most visited sites on the Internet for pharma decision-makers looking for the latest breaking news. Why not put this traffic to work for you? It costs only a fraction of other on-line publications with far fewer readers. For further information, please feel free to contact us: http://www.worldpharmanews.com/contact-us
With best regards,
Ruslan David
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany.
eHealthNews.eu | eHealthServer.com | eHealthServer.de | Health IT Space | World Pharma News | PharmaNews.eu
Administrator/Editor
DAVID eHealth & Pharma UG,
Saarland University, Starterzentrum, Building A1 1,
66123, Germany.
eHealthNews.eu | eHealthServer.com | eHealthServer.de | Health IT Space | World Pharma News | PharmaNews.eu
Reply all
Reply to author
Forward
0 new messages